SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C
http://www.w3.org/2000/01/rdf-schema#comment
"Beta-synuclein decreased formation of Lewy bodies by 40% and prevented functional deficits associated with overexpression of alpha-synuclein. This is a preliminary in vivo proof of antiaggregatory function of beta-synuclein."
xsd:string
http://purl.uniprot.org/uniprot/#_54D13CC11D8D24C13A6FD7153F62EEA6367CE62F339A37B1DA60EB1D21948F10307075BAA5A9FF27B8B219B95307ED5C
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C
http://purl.uniprot.org/uniprot/Q91ZZ3
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C
http://purl.uniprot.org/uniprot/#_Q91ZZ3-mappedCitation-12212795
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/5173CB396376823DD8366352D7E351FCDDC9D3A2C1EAF79C252A27A9E63C90E6D929C3C6776733ADA221C0B91D2C239C